SCM
NBIX icon

Superstring Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Superstring Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,608
Closed -$5.1M – 40
2025
Q2 		$5.1M Buy
+40,608
New +$4.66M 6.04% 3
2024
Q1 		– Sell
-29,346
Closed -$3.87M – 42
2023
Q4 		$3.87M Buy
+29,346
New +$3.38M 2.76% 11

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Superstring Capital Management's NBIX Position: Q3 2025 in Review

Superstring Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 40,608 shares — an estimated $5.1M sold.

Superstring Capital Management first reported a position in NBIX in Q4 2023 and held it in 2 quarters. The position peaked at $5.1M in Q2 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Superstring Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Superstring Capital Management sold 40,608 Neurocrine Biosciences shares in Q3 2025, an estimated $5.1M.
  • Superstring Capital Management first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 2 quarters.
  • Superstring Capital Management's Neurocrine Biosciences position peaked at $5.1M in Q2 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.